Back

Increasing the prescription rate of β-blockers is beneficial for patients with chronic obstructive pulmonary and cardiovascular disease

European Heart Journal

5 May 2021
Organised by: Logo
Read full article
ESC Journals

Contributors

Yan-Li Yang
Yan-Li Yang

Author

Zi-Jian Xiang
Zi-Jian Xiang

Author

Ruo-Lan Xiang
Ruo-Lan Xiang

Author

You may be interested in
thumbnail
Congress Presentation
Beta-blockers in patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: cardiovascular and respiratory outcomes
19 May 2025
thumbnail
Congress Presentation
Tends in beta-blocker administration and in prevalence of indications for their usage in heart failure with preserved ejection fraction: an analysis of randomized clinical trials
27 August 2021
thumbnail
Congress Presentation
β-blocker adherence trajectories and 5-year clinical outcomes in PCI-treated ACS patients with LVEF ≥50%: a group-based trajectory modeling analysis
31 August 2026
thumbnail
Congress Session
Optimal management of chronic coronary syndromes: putting the evidence into practice
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources